Plant virus-based immunotherapy for solid tumors
Official title: SBIR: Plant virus immunotherapy for solid tumors
Funded at Plantiosx INC · NIH-11402144 · Data updated 2026-11-12
A small, early-stage program aims to develop a plant virus-based therapy injected into tumors to help the body fight solid cancers.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Plantiosx INC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $406,500 |
| NIH project number | 1R43CA314457-01 |
| Project ID | NIH-11402144 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with solid tumors who could be eligible for early clinical testing of a novel intratumoral immunotherapy.
✕Less likely to help
Patients with cancers unlikely to respond to intratumoral immunotherapy or who have conditions excluding study participation.
What this research studies
This project focuses on translating a plant virus immunotherapy into a clinical option for cancer patients. It progresses from manufacturing and safety studies to planned early human trials, with an emphasis on scalable chemistry, manufacturing, and controls and toxicology work. If successful, it could enable more effective, localized immune activation against tumors and trigger broader anti-cancer responses.
Why it matters
Potential benefit: It could provide a novel, targeted cancer treatment with the potential for durable responses and improved safety.
How similar studies have gone: Prior canine cancer trials and murine studies suggest promising anti-tumor activity, supporting translational potential to humans.
Where this research is happening
-
Plantiosx INC
San Diego, United States Active
Researchers
- Principal investigator: Shukla, Sourabh — Plantiosx INC
- Study coordinator: Shukla, Sourabh
Related research
Other NIH-funded projects on the same topics.
-
Oral Microbiome–Based Aid to Immunotherapy for Refractory Solid Tumors
A mouth-to-tumor therapy using a probiotic-like approach to help immune checkpoint drugs work better for patients whose solid tumors don’t respond well to current treatments.
-
A new immunotherapy to improve solid tumor treatment
This project is developing a new type of immunotherapy to help more people with solid tumors like lung cancer and melanoma.
-
Targeting specific immune cells to improve cancer treatment
This study is testing a new treatment that aims to help your immune system fight solid tumors like lung cancer and melanoma by targeting certain cells that block its natural response, and it’s designed to be safer and more effective than previous options.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.